All exams were performed using a 1.5T scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany), equipped with an 18-channel body array coil. The study protocol consisted of the following sequences: 1) standard abdominal MRI sequences: coronal and axial T2 half-Fourier single-shot turbo spin-echo (HASTE), liver iron and fat quantification with multiecho Dixon (LiverLab), T1 volumetric interpolated breath-hold examination [VIBE] before and after administration of 10 ml of gadoxetate disodium (Eovist/Primovist, Bayer Healthcare Pharmaceuticals, New Jersey, USA) at 2ml/s, T2* mapping (time to echo: 2.3–14.2 msec), and diffusion-weighted imaging, 2) research sequences: T1ρ, pre-contrast T1 mapping, T1-HBP, 4D flow imaging, dynamic contrast-enhanced MRI, and MRE [5 (link), 35 (link)]. The data relevant to T1ρ, 4D flow imaging, dynamic contrast-enhanced MRI, and MRE are not included in the current study and have been or will be reported separately [37 (link), 38 (link)].